Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max S Topp

Showing results (71-80 of 122) with videos related to

Pageof 13
Sort By:
Blood|May 18, 2012
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomabMatthias Klinger, Christian Brandl, Gerhard Zugmaier, et al.
American Journal of Hematology|November 28, 2017
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expressionElias Jabbour, Johannes Düll, Musa Yilmaz, et al.
Nuklearmedizin. Nuclear Medicine|January 8, 2024
CXCR4-targeted Theranostics in Hematooncology: Opportunities and ChallengesRudolf Werner, Alexander Haug, Christian Buske, et al.
Blood|May 31, 2023
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studiesDennis A Eichenauer, Ina Bühnen, Christian Baues, et al.
Blood|August 23, 2017
Hematopoietic stem cell involvement in <i>BCR-ABL1-</i>positive ALL as a potential mechanism of resistance to blinatumomab therapyInga Nagel, Marius Bartels, Johannes Duell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trialBastian von Tresckow, Annette Plütschow, Michael Fuchs, et al.
Blood|January 24, 2018
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemiaNicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 5, 2023
Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone LymphomaJohannes Duell, Andreas K Buck, Philipp E Hartrampf, et al.
Blood|November 17, 2023
Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapyJohannes Duell, Alexander M Leipold, Silke Appenzeller, et al.
Leukemia|March 23, 2024
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemiaThomas Burmeister, Aeint-Steffen Ströh, Britta Kehden, et al.
Pageof 13

Showing results (71-80 of 122) with videos related to

Sort By:
Pageof 13
Blood|May 18, 2012
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomabMatthias Klinger, Christian Brandl, Gerhard Zugmaier, et al.
American Journal of Hematology|November 28, 2017
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expressionElias Jabbour, Johannes Düll, Musa Yilmaz, et al.
Nuklearmedizin. Nuclear Medicine|January 8, 2024
CXCR4-targeted Theranostics in Hematooncology: Opportunities and ChallengesRudolf Werner, Alexander Haug, Christian Buske, et al.
Blood|May 31, 2023
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studiesDennis A Eichenauer, Ina Bühnen, Christian Baues, et al.
Blood|August 23, 2017
Hematopoietic stem cell involvement in <i>BCR-ABL1-</i>positive ALL as a potential mechanism of resistance to blinatumomab therapyInga Nagel, Marius Bartels, Johannes Duell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trialBastian von Tresckow, Annette Plütschow, Michael Fuchs, et al.
Blood|January 24, 2018
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemiaNicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 5, 2023
Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone LymphomaJohannes Duell, Andreas K Buck, Philipp E Hartrampf, et al.
Blood|November 17, 2023
Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapyJohannes Duell, Alexander M Leipold, Silke Appenzeller, et al.
Leukemia|March 23, 2024
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemiaThomas Burmeister, Aeint-Steffen Ströh, Britta Kehden, et al.
Pageof 13